


## Africa/Middle East



## Asia/Pacific



ASRS  
GLOBAL  
TRENDS  
IN RETINA

## Europe




## Latin America



ASRS American Society of  
Retina Specialists

2015



---


**ASRS**  
**GLOBAL**  
**TRENDS**  
**IN RETINA**

---

Kourous A. Rezaei, MD



## ASRS International Affairs



### Preferences and Trends (PAT) Survey

**36** societies accepted our invitation;  
**1059** of their members answered the  
2015 Global Trends in Retina Survey

# GLOBAL TRENDS in Retina

## ASRS International Affairs Committee

Kourous A. Rezaei, MD, Chair


Andre V. Gomes, MD, PhD

Anat Loewenstein, MD

Sachin S. Mudvari, MD

John S. Pollack, MD

Asheesh Tewari, MD



# GLOBAL TRENDS in Retina

## International Liaison Leaders

J. Fernando Arevalo, MD, FACS (Americas)


Alay S. Bunker, MD (Asia/Pacific)

Ehab N. El-Rayes, MD, PhD (Africa/Middle East)

José Garcia Arumi, MD, PhD (Europe)

## International Affairs Committee Staff Liaison

Caroline Bozell, MS



# GLOBAL TRENDS in Retina


## ASRS PAT Survey Editors

Thomas W. Stone, MD, *Editor*

Susan Raef, MSMC, *Managing Editor*

## Research Consultant

Mindy Schneiderman, PhD



# GLOBAL TRENDS in Retina

## Panelists

### Africa/Middle East

Ehab N. El-Rayes, MD, PhD

Ogugua Ndubuisi Okonkwo, MD, FRCS(Edin)

### Asia/Pacific

Alay S. Banker, MD


Akito Hirakata, MD

### Europe

Ursula M. Schmidt-Erfurt, MD

Malhar Soni, DO, MS, DNB, FRCS

Carlos Mateo, MD



# GLOBAL TRENDS in Retina


## Panelists

### Latin America

Michel Eid Farah, MD, PhD  
Guillermo Iribarren, MD

### United States

Jay S. Duker, MD  
Peter K. Kaiser, MD  
Baruch D. Kuppermann, MD, PhD





ARAB AFRICAN SOCIETY  
of Retina Specialists  
المؤتمر العربي الأفريقي  
لدراسات الشبكية



ILOS  
איגוד רופאי העיניים בישראל  
ISRAEL OPHTHALMOLOGY SOCIETY



Iranian Vitreoretina Society

Israel Vitreoretinal Society

Jordanian Ophthalmological Society



Lebanese Ophthalmological Society




Oman Ophthalmic Society



Saudi Ophthalmological Society



Vitreo Retinal Society of Nigeria



## Asia/Pacific



Association of Vitreo-Retina Specialists of Sri Lanka



Australian and New Zealand Society  
of Retina Specialists



Chinese Ocular Fundus Society



Indonesia Ophthalmology Association  
Vitreoretinal Interest Group



Japanese Retina and Vitreous Society



Singapore Society of Ophthalmology




Taiwan Retina Society



The Thai Retina Society



Vitreo-Retinal Society of India



## Europe



Austrian Ophthalmological Society

British and Eire Association of Vitreoretinal Surgeons

Dutch Society of Vitreoretinal Surgery

European Society of Retina Specialists

European VitreoRetinal Society


French Society of Retina Specialists

Greek Vitreo-Retinal Society

Italian Vitreoretinal Surgery Group

Spanish Retina and Vitreous Society

Turkish Ophthalmological Society



## Latin America



Argentine Retina and Vitreous Society

Brazilian Retina and Vitreous Society

Colombian Retina and Vitreous Association

Costa Rican Association of Ophthalmology


Mexican Retina Association

Pan-American Retina and Vitreous Society



Peruvian Society of Ophthalmology

Salvadoran Retina and Vitreous Association


Uruguayan Association of Ophthalmology




# In general, how do you treat wet-AMD patients with active CNV?





# After how many injections do you consider switching anti-VEGF agents due to inadequate response?




# How would you treat a recent CRVO with vision-affecting macular edema?




# What is your initial treatment choice for a 72-year-old patient with BRVO, macular edema, and VA = 20/60 (decreased vision)?




# How do you generally treat patients with vein occlusion and macular edema associated with decreased vision?




# After how many injections do you consider an alternative anti-VEGF therapy for DME in a non-responder?




# How would you initially treat a young diabetic patient with both severe DME and advanced PDR?





# How long do you wait before considering surgery in a diabetic patient with nonclearing vitreous hemorrhage?




# Which vitrectomy machine do you prefer?




# In what percentage of your retinal detachment cases do you place a scleral buckle?




# In what percentage of *ERM* cases do you peel ILM?





# How long do you recommend facedown positioning after macular hole repair?





# What is your general vitrectomy treatment plan for patients with a dislocated IOL and no capsular bag?




# How would you treat acute endophthalmitis after intravitreal injection in a pseudophake with HM vision?



# How often do you perform a fluid-air exchange just to reduce sclerotomy leakage?



2015



---

**ASRS**  
**GLOBAL**  
**TRENDS**  
**IN RETINA**

---

Thank You